Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
3
×
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
fda
ipo
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
acetylon pharmaceuticals
advaxis
aimmune therapeutics
alder biopharmaceutical
alder biopharmaceuticals
alexander hardy
allergan
ambys medicines
american academy of neurology
amgen
andrew oxtoby
atogepant
What
big
3
×
make
new
aiming
ambys
approval
arguments
bio
biotech
bosley's
bosley’s
bridge
bucks
cas
ceo
class
commercialized
companies
competitors
control
crime
crispr
deadly
deal
debuted
decades
departure
diseases
drug
drugs
editas
exit
fda
formed
future
guiding
katrine
launch
liver
medicine
Language
Current search:
big
×
biotech
×
" san diego top stories "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?